Page results
-
Our thoracic/respiratory medicine service offers a comprehensive inpatient and outpatient medical service for adults with conditions affecting the lungs.
-
The UCLH Department of Rheumatology is a UK centre of excellence for clinical care, training and research.
-
This information has been written to help you now that your radiotherapy treatment is finishing.
-
This page is for patients who are having stereotactic ablative body radiotherapy (SABR) for lung cancer.
-
Information about activating your MyCare UCLH app.
-
This page has been written for patients who are having a course of superficial radiotherapy for a skin tumour (such as a basal cell carcinoma or squamous cell carcinoma), or some other skin condition.
-
Concerned about the impact of climate change on people with neurological conditions, Professor Sanjay Sisodiya has established established a consortium of neurological specialists and will be undertaking research.
-
Information about having a gadolinium-based contrast agent for MRI examinations while breastfeeding.
-
This page is aimed at providing guidance and recommendations for patients, carers or family members following a high dose examination or procedure performed in the Neuroradiology department at NHNN, which involved ionising radiation.
-
A high quality diagnostic service for surgical neuropathology, neuromuscular diagnostics, epilepsy, molecular neuropathology of brain tumours, and neurodegenerative diseases.
File results
-
FOI/2023/0007 - Outpatient activity for 2022
-
FOI/2023/0009 - Procedure volumes/ average costs for portable and stable oxygen concentrator devices
-
FOI/2023/0010 - Bardet-biedle Syndrome patient treatment and diagnosis
-
FOI/2023/0013 - Average waiting times for colonoscopy investigations
-
FOI/2023/0014 - Surgery protocols/ standard operating procedures for a feticide
-
FOI/2023/0018 - A&E attendances/ admissions by patients of no fixed abode
-
FOI/2023/0019 - Public access to water refill stations on your premises
-
FOI/2023/0022 - Guidelines staff follow for patients with disabilities and autism
-
FOI/2023/0226 - Treatment with Nivolumab
-
FOI/2023/0225 - Usage of Dabrafenib + Trametinib in cancer treatment